Loading...
XASXACW
Market cap50mUSD
Jan 08, Last price  
0.03AUD
1D
4.00%
1Q
-7.14%
Jan 2017
-63.89%
IPO
-95.14%
Name

Actinogen Medical Ltd

Chart & Performance

D1W1MN
XASX:ACW chart
P/E
—
P/S
8.20
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.55%
Rev. gr., 5y
15.35%
Revenues
10m
+103.18%
155,875128,12692,80194,45351,5623,102181,204153,4293,952,9431,415,4863,300,7354,862,7553,516,3971,984,0723,640,0824,887,9359,931,504
Net income
-13m
L+21.32%
-435,658-926,942-737,471-742,380-1,529,156-164,663-440,222-5,431,009-3,633,758-3,190,338-6,230,609-9,887,682-5,330,529-3,915,067-9,497,370-10,752,270-13,044,282
CFO
-17m
L+94.88%
-397,223-546,874-727,365-805,704-823,941-125,565-437,837-3,719,789-5,039,139-1,108,799-7,911,052-10,498,298-2,855,613-1,723,902-9,517,132-8,698,241-16,950,870
Earnings
Feb 24, 2025

Profile

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
URL
https://actinogen.com.au/
IPO date
Oct 16, 2007
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
9,932
103.18%
4,888
34.28%
3,640
83.47%
Cost of revenue
22,770
15,873
13,173
Unusual Expense (Income)
NOPBT
(12,839)
(10,985)
(9,533)
NOPBT Margin
Operating Taxes
(9,932)
(4,888)
(3,640)
Tax Rate
NOPAT
(2,907)
(6,097)
(5,893)
Net income
(13,044)
21.32%
(10,752)
13.21%
(9,497)
142.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
18,041
903
11,660
BB yield
-13.38%
-1.20%
-13.04%
Debt
Debt current
61
87
78
Long-term debt
577
87
174
Deferred revenue
Other long-term liabilities
(1)
Net debt
(8,813)
(8,286)
(16,118)
Cash flow
Cash from operating activities
(16,951)
(8,698)
(9,517)
CAPEX
(8)
(37)
(3)
Cash from investing activities
(8)
(37)
(3)
Cash from financing activities
17,950
825
12,420
FCF
(8,861)
(5,909)
(7,503)
Balance
Cash
9,451
8,460
16,370
Long term investments
Excess cash
8,954
8,216
16,188
Stockholders' equity
19,696
20,605
28,071
Invested Capital
11,061
5,278
5,717
ROIC
ROCE
EV
Common stock shares outstanding
2,174,301
1,875,607
1,787,680
Price
0.06
55.00%
0.04
-20.00%
0.05
-61.54%
Market cap
134,807
79.68%
75,024
-16.07%
89,384
-53.00%
EV
125,994
66,738
73,266
EBITDA
(12,422)
(10,580)
(9,133)
EV/EBITDA
Interest
24
17
18
Interest/NOPBT